Grombirikova, Hana
Bily, Viktor
Soucek, Premysl
Kramarek, Michal
Hakl, Roman
Ballonova, Lucie
Ravcukova, Barbora
Ricna, Dita
Kozena, Karolina
Kratochvilova, Lucie
Sobotkova, Marta
Zachova, Radana
Kuklinek, Pavel
Kralickova, Pavlina
Krcmova, Irena
Hanzlikova, Jana
Vachova, Martina
Krystufkova, Olga
Dankova, Eva
Jesenak, Milos
Novackova, Martina
Svoboda, Michal
Litzman, Jiri
Freiberger, Tomas http://orcid.org/0000-0001-6532-7053
Funding for this research was provided by:
Ministerstvo Zdravotnictví Ceské Republiky (NV18-05-00330)
Ministerstvo Školství, Mládeže a Tělovýchovy (MUNI/A/1098/2022, MUNI/A/1098/2022)
Masaryk University
Article History
Received: 23 February 2023
Accepted: 2 August 2023
First Online: 25 August 2023
Declarations
:
: This is an observational study. Therefore, no ethical approval was required.
: All participants gave their informed written consent for molecular genetic analysis of their samples. In addition, they provided written consent to collect and analyze their data.
: Informed consent to publish their data was obtained from all individual participants included into the study.
: Authors RH and PK have received speaker and consultant honoraria from Shire and Takeda, and RH served as a principal investigator in the clinical trials supported by BioCryst Pharmaceuticals, Phavaris Netherands, Kalvista, Pharming, and CSL Behring. MaS has received speaker and consultant honoraria from Takeda, Pharming and Kalvista; travel support from CSL Behring and Takeda. RZ has received speaker, and consultant honoraria from CSL Behring and Takeda. MJ has received speaker and consultant honoraria from Takeda, Pharming, CSL Behring, Novartis, Zentiva, SOBI, ALK, Stallergenes-Greer, Chiesi, BerlinChemie Menarini and GSK; travel support from Company Novartis, Takeda, CSL Behring and ALK, and served as a principal investigator in the clinical trials supported by BioCryst Pharmaceuticals, Kalvista, Pharming, and Takeda. TF received speaker honoraria from Takeda. Authors HG, VB, PS, MK, LB, BR, DR, KK, LK, PK, IK, MV, OK, JH, ED, MN, MiS, and JL have no relevant financial or non-financial interests to disclose.